Pharma Pricing and Reimbursement Outlook: Optimizing price and market access in a recessionary climate
NEW YORK, Oct. 27, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
http://www.reportlinker.com/p0165652/Pharma-Pricing-and-Reimbursement-Outlook-Optimizing-price-and-market-access-in-a-recessionary-climate.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Health_Insurance
Determining the correct pricing and reimbursement strategy for a new product is an essential component of gaining maximum return on investment. This report gives an up to date and comprehensive review of the pricing and reimbursement environment in the seven major pharmaceutical markets and also the four high-growth emerging markets, as well as providing analysis of the most likely future scenarios in these markets' pricing and reimbursement environments. The report also provides strategic guidance on approaches that can be taken to ensure that a product achieves the most favorable pricing and reimbursement positioning
Table of Contents
Pharma pricing and reimbursement outlook
Executive Summary 10
Pricing and reimbursement in context 10
US pricing and reimbursement trends 11
European pricing and reimbursement trends 12
Pricing and reimbursement trends in Japan and the rest of the world 13
Global pricing and market access strategies 14
Pricing and market access planning 15
Chapter 1 Pricing and reimbursement in context 18
Summary 18
Introduction 19
Healthcare cost containment 19
Declining R&D productivity levels 24
Patent expiries and the impact of generics 28
The trickle-down effect of global recession 30
Pharmaceutical pricing and reimbursement outlook 32
Chapter 2 US pricing and reimbursement trends 36
Summary 36
Introduction 37
US pricing and reimbursement regulations 37
Private healthcare insurance 38
Medicare 40
Medicaid 42
Key pricing and market access issues 44
Patent expiries and generics 44
Follow-on biologics 45
Cost-effectiveness and budget impact 47
Innovative pricing agreements 48
Medicare part D impact and funding 49
President Obama's healthcare reform plans 51
Economic recession 52
Future trends in US pricing and reimbursement 53
Most likely scenario 55
Best case scenario 55
Worst case scenario 56
Chapter 3 European pricing and reimbursement trends 58
Summary 58
Introduction 59
European pricing and reimbursement regulations 59
French pricing and reimbursement regulations 62
German pricing and reimbursement regulations 65
Italian pricing and reimbursement regulations 67
Spanish pricing and reimbursement regulations 73
UK pricing and reimbursement regulations 76
Key pricing and market access issues 78
Decentralization 78
Generics 79
Parallel trade 80
Cost-effectiveness studies 81
Innovative pricing agreements 81
Economic recession 82
Future trends in European pricing and reimbursement 83
Most likely scenario 85
Best case scenario 86
Worst case scenario 86
Chapter 4 Pricing and reimbursement trends in Japan and the rest of the world 90
Summary 90
Introduction 91
Japanese pricing and reimbursement regulations 91
Key pricing and market access issues in Japan 94
Biennial price cuts 94
Generic pricing and substitution 96
Innovative drug pricing 97
Future trends in Japanese pricing and reimbursement 98
Most likely scenario 100
Best case scenario 101
Worst case scenario 101
High growth emerging pharmaceutical markets 102
Pricing and reimbursement in Brazil 104
Pricing and reimbursement in Russia 104
Pricing and reimbursement in India 105
Pricing and reimbursement in China 105
Chapter 5 Global pricing and market access strategies 108
Summary 108
Introduction 109
Local optimization 109
Price differentials 109
Market access differentials 111
Global coordination 113
Launch sequence 113
Price differentials 115
Balancing local optimization and global coordination 119
Chapter 6 Pricing and market access planning 122
Summary 122
Introduction 123
Pricing research and modeling 123
Research methodology 123
Pricing models 126
Pharmacoeconomic models 131
Pricing across the lifecycle 136
Pricing in early stage R&D 137
Pricing in late stage R&D 137
Pricing for lifecycle management 138
Pricing for pharmacoeconomic planning 138
List of Figures
Figure 1.1: Trends in healthcare spend as a proportion of GDP, 1990-2007 21
Figure 1.2: Pharmaceutical expenditure as a share of total healthcare expenditure, 1990-2007 22
Figure 1.3: R&D productivity levels, 1999-2008 25
Figure 1.4: The rising cost of new drug development, 1975-2006 27
Figure 1.5: Impact of US patent expiries for leading drugs, 2008-2013 28
Figure 1.6: Generics market share by sales value, 2003-2007 29
Figure 1.7: Quarterly GDP growth, Q4 2007 – Q2 2009 31
Figure 2.8: Projections of total Medicare Part D spending, FY2007-2016 50
Figure 2.9: Future scenarios for pharmaceutical pricing and reimbursement in the US 54
Figure 3.10: Pharmaceutical price controls in major European markets 61
Figure 3.11: Pharmaceutical reimbursement systems in major European markets 62
Figure 3.12: Italian categorization for innovative new therapies 69
Figure 3.13: Future scenarios for pharmaceutical pricing and reimbursement in the major European markets 84
Figure 4.14: The Japanese National Health Insurance system, FY2008 92
Figure 4.15: Average NHI price cuts, 1998-2008 95
Figure 4.16: Future scenarios for pharmaceutical pricing and reimbursement in Japan 99
Figure 4.17: Real GDP growth in BRIC and major markets, 2008 103
Figure 5.18: International price differentials for leading drugs, 2008 110
Figure 5.19: Market share for new products launched in last five years, 2007 112
Figure 5.20: Delays in European market access, 2007 114
Figure 5.21: External reference pricing in Europe, 2009 116
Figure 5.22: Parallel imports as a share of pharmacy sales in Europe, 2007 118
Figure 6.23: Price demand and response curves 128
Figure 6.24: Market share and revenue impact of reimbursement and formulary status 130
Figure 6.25: Budget impact modeling 135
List of Tables
Table 1.1: Trends in healthcare spend as a proportion of GDP, 1990-2007 20
Table 1.2: Number of NME and BLA approvals by the FDA, 1999-2008 24
Table 1.3: R&D expenditure by PhRMA members, 1999-2008 26
Table 4.4: NHI price premium classifications for new drugs 93
Table 6.5: Pricing across the drug development and marketing lifecycle 137
To order this report:
Pharmaceutical Industry: Pharma Pricing and Reimbursement Outlook: Optimizing price and market access in a recessionary climate
Check our Real Time Industry Data
CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article